Nexalin Technology (NASDAQ:NXL) is a medical device company that develops and markets non-invasive neuromodulation therapies for the treatment of mood and sleep disorders. Through its flagship product, the Nexalin® device, the company offers an electrotherapy platform designed to deliver proprietary waveforms to targeted regions of the brain. These waveforms are intended to modulate neural activity and provide a drug-free alternative for patients suffering from anxiety, depression, insomnia and related conditions. The Nexalin system has received FDA 510(k) clearance for over-the-counter use, reflecting its focus on safety and ease of home administration.
Founded in the early 2000s and headquartered in Florida, Nexalin Technology initially concentrated on clinical research and development before expanding into the consumer wellness market. The company has collaborated with academic and clinical partners to conduct pilot studies and gather real-world data on its neuromodulation approach. These efforts have helped to refine treatment protocols and support broader adoption among healthcare practitioners, including psychiatrists, psychologists and primary care physicians who seek complementary or adjunctive treatment options for their patients.
While Nexalin’s primary market remains the United States, the company has pursued distribution agreements and regulatory pathways in select international markets. It maintains a network of medical device distributors and telehealth partnerships to facilitate product availability and patient support. In addition, Nexalin has invested in digital platforms and remote monitoring tools to track patient progress and treatment outcomes, underscoring its commitment to integrating technology and clinical science in mental health care.
Leadership at Nexalin Technology is anchored by Chief Executive Officer Bradley Christian, whose background spans medical device commercialization and strategic growth initiatives. The executive team includes seasoned professionals in clinical affairs, regulatory compliance and manufacturing, all focused on scaling production and supporting ongoing research. Under this leadership, Nexalin continues to pursue product enhancements, new waveform protocols and expanded access to its neuromodulation therapies for individuals seeking innovative, non-pharmaceutical treatment options.
